Core Viewpoint - Chao Yan Co., Ltd. has shown a positive performance in stock trading and financial results, indicating growth potential in the medical imaging and industrial non-destructive testing equipment sectors [1][2]. Financial Performance - As of June 30, 2025, Chao Yan Co., Ltd. achieved a revenue of 184 million yuan, representing a year-on-year growth of 15% [2]. - The net profit attributable to shareholders for the same period was approximately 68.45 million yuan, reflecting an 18.5% increase compared to the previous year [2]. Stock Trading Activity - On October 14, 2023, Chao Yan Co., Ltd. saw a stock price increase of 2.24%, with a trading volume of approximately 92.23 million yuan [1]. - The financing buy-in amount for the same day was 6.48 million yuan, while the financing repayment was 6.92 million yuan, resulting in a net financing buy-in of -0.43 million yuan [1]. - The total financing and securities balance as of October 14, 2023, was approximately 95.63 million yuan [1]. Shareholder Information - As of June 30, 2025, the number of shareholders for Chao Yan Co., Ltd. was 22,300, a decrease of 16.65% from the previous period [2]. - The average number of circulating shares per shareholder increased by 19.98% to 2,456 shares [2]. Dividend Distribution - Chao Yan Co., Ltd. has distributed a total of 43.69 million yuan in dividends since its A-share listing [3]. Institutional Holdings - As of June 30, 2025, the largest circulating shareholder was Huabao Zhongzheng Medical ETF, holding 1.91 million shares as a new shareholder [3]. - Other notable institutional shareholders include Southern Zhongzheng 1000 ETF and Hong Kong Central Clearing Limited, with significant shareholdings and increases [3].

Core Insights - The stock of Chao Yan Co., Ltd. experienced a decline of 1.60% on October 13, with a trading volume of 51.83 million yuan [1] - The company reported a financing net buy of -67,400 yuan on the same day, with a total financing and securities balance of 96.02 million yuan [1] Financing and Trading Data - On October 13, Chao Yan Co., Ltd. had a financing buy amount of 5.56 million yuan and a financing repayment of 5.62 million yuan [1] - The current financing balance is 95.85 million yuan, accounting for 6.68% of the circulating market value [1] - The company had no shares repaid in the securities lending segment, with 3,100 shares sold, amounting to 76,200 yuan at the closing price [1] Company Overview - Chao Yan Co., Ltd. is located in Shantou, Guangdong Province, and was established on November 15, 1982, with a listing date set for January 22, 2025 [1] - The company specializes in the research, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, recognized as a national key high-tech enterprise [1] - The revenue composition includes 71.16% from medical ultrasound, 17.30% from industrial ultrasound, 5.72% from accessories, 4.56% from X-ray, and 1.26% from other sources [1] Financial Performance - As of June 30, the number of shareholders for Chao Yan Co., Ltd. was 22,300, a decrease of 16.65% from the previous period [2] - The average number of circulating shares per person increased by 19.98% to 2,456 shares [2] - For the first half of 2025, the company achieved a revenue of 184 million yuan, representing a year-on-year growth of 15.00%, and a net profit attributable to shareholders of 68.45 million yuan, up 18.50% year-on-year [2] Dividend and Shareholding Structure - Chao Yan Co., Ltd. has distributed a total of 43.69 million yuan in dividends since its A-share listing [3] - As of June 30, 2025, the largest circulating shareholder is Huabao CSI Medical ETF, holding 1.91 million shares as a new shareholder [3] - Other notable shareholders include Southern CSI 1000 ETF and Hong Kong Central Clearing Limited, with increases in their holdings compared to the previous period [3]

证券日报网讯 10月13日晚间，超研股份发布公告称，公司于2025年10月11日召开了职工代表大会，经 与会职工代表表决，同意选举陈宏龙先生担任公司第二届董事会职工代表董事。 （文章来源：证券日报） ...

证券代码：301602 证券简称：超研股份 公告编号：2025-047 汕头市超声仪器研究所股份有限公司 关于选举产生第二届董事会职工代表董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 根据《中华人民共和国公司法（2023 年修订）》（以下简称"《公司法》"） 及汕头市超声仪器研究所股份有限公司章程（以下简称"《公司章程》"）等有 关规定，为保证汕头市超声仪器研究所股份有限公司（以下简称"公司"）董事 会的合规运作，公司于 2025 年 10 月 11 日召开了职工代表大会，经与会职工代 表表决，同意选举陈宏龙先生担任公司第二届董事会职工代表董事，任期自职工 代表大会审议通过之日起至公司第二届董事会任期届满之日止。 董事会 2025 年 10 月 13 日 附件：陈宏龙先生简历 陈宏龙先生，中国国籍，无境外永久居留权，1969 年 10 月出生，本科学历。 1992 年 7 月至 2008 年 12 月，历任汕头超声仪器研究所技术员、副主任、主任、 办公室主任、所长助理、副所长；2008 年 12 月至 2020 年 9 月，历任汕头市超 声仪器研 ...

证券代码：301602 证券简称：超研股份 公告编号：2025-046 汕头市超声仪器研究所股份有限公司 关于新增募集资金专户并签订募集资金专户存储三方监管 协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 汕头市超声仪器研究所股份有限公司（以下简称"公司"）于 2025 年 8 月 26 日分别召开第二届董事会第九次会议和第二届监事会第六次会议，审议通过 了《关于部分募投项目增加实施主体及募集资金专户的议案》，同意募投项目"工 业无损检测系统研发项目"的实施主体由公司增加为公司和全资子公司汕头市超 声检测科技有限公司(以下简称"超声检测")，实施地点不变，同意超声检测设 立募集资金专户，用于"工业无损检测系统研发项目"募集资金的存放、管理和 使用。同意公司以募集资金向超声检测增资 2,200 万元人民币，具体内容详见公 司在巨潮资讯网披露的《关于部分募投项目增加实施主体及募集资金专户的公告》 （公告编号：2025-040）。 近日，公司和全资子公司超声检测会同保荐机构中国银河证券股份有限公司 与创兴银行有限公司汕头分行签订了《募集资金专户存储三方监 ...

Core Viewpoint - Chao Yan Co., Ltd. experienced a slight decline in stock price on September 25, with a trading volume of 46.03 million yuan and a net financing outflow of 1.95 million yuan, indicating a cautious market sentiment towards the company [1][2]. Financing Summary - On September 25, Chao Yan Co., Ltd. had a financing buy amount of 2.72 million yuan, with a total financing balance of 99.58 million yuan, accounting for 6.90% of its market capitalization [2]. - The company had no shares repaid in the securities lending market, with 100 shares sold, amounting to 2,474 yuan at the closing price, and a remaining securities lending balance of 96,500 yuan [2]. Business Overview - Chao Yan Co., Ltd., established on November 15, 1982, is located in Shantou, Guangdong Province, and specializes in the research, development, production, and sales of medical imaging and industrial non-destructive testing equipment [2]. - The company's revenue composition includes medical ultrasound (71.16%), industrial ultrasound (17.30%), accessories (5.72%), X-ray (4.56%), and other supplementary products (1.26%) [2]. Financial Performance - For the first half of 2025, Chao Yan Co., Ltd. reported a revenue of 184 million yuan, representing a year-on-year growth of 15.00%, and a net profit attributable to shareholders of 68.45 million yuan, reflecting an 18.50% increase compared to the previous year [2]. Shareholder Information - As of June 30, 2025, the number of shareholders for Chao Yan Co., Ltd. was 22,300, a decrease of 16.65% from the previous period, while the average number of circulating shares per shareholder increased by 19.98% to 2,456 shares [2]. - The top shareholders include Huabao Zhongzheng Medical ETF, which is the largest shareholder with 1.91 million shares, and several new institutional investors have entered the shareholder list [3].

Core Viewpoint - Chao Yan Co., Ltd. has shown a positive financial performance with a revenue increase of 15% year-on-year and a net profit growth of 18.5% for the first half of 2025, indicating strong operational capabilities and market demand [2]. Financial Performance - For the period from January to June 2025, Chao Yan Co., Ltd. achieved a revenue of 184 million yuan, reflecting a year-on-year growth of 15% [2]. - The net profit attributable to the parent company for the same period was approximately 68.45 million yuan, which represents an 18.5% increase compared to the previous year [2]. - Cumulative cash dividends distributed by the company since its A-share listing amount to approximately 43.69 million yuan [2]. Shareholder Structure - As of June 30, 2025, the number of shareholders for Chao Yan Co., Ltd. was 22,300, a decrease of 16.65% from the previous period [2]. - The average number of circulating shares held per shareholder increased by 19.98% to 2,456 shares [2]. - The top circulating shareholder is Huabao Zhongzheng Medical ETF, holding 1.91 million shares as a new shareholder [2]. Trading Activity - On September 24, 2025, Chao Yan Co., Ltd. saw a stock price increase of 1.52%, with a trading volume of approximately 48.73 million yuan [1]. - The financing buy-in amount for the same day was 2.94 million yuan, while the financing repayment was 10.16 million yuan, resulting in a net financing outflow of 7.22 million yuan [1]. - The total balance of margin trading for Chao Yan Co., Ltd. as of September 24, 2025, was approximately 102 million yuan, accounting for 7.03% of its market capitalization [1].

Core Viewpoint - The company is focused on applying ultrasound and ray technology across various fields to meet diverse user needs, with a particular emphasis on ultrasound applications in the brain area, where it has achieved multiple patents and software copyrights [2]. Group 1 - The company has developed various models of ultrasound diagnostic products specifically for brain examinations [2]. - The application of ultrasound in the brain is a key area of research and development for the company [2]. - Detailed information regarding the company's patents and software copyrights can be found in its prospectus and periodic reports [2].

Group 1: Company Strategy and Focus Areas - The company aims to enhance its core competitiveness through industrial investments, focusing on the medical imaging and non-destructive testing sectors [2][3] - The company is actively seeking acquisition opportunities that align with its strategic development [2][3] - The company plans to expand its product portfolio through both depth and breadth, targeting cross-sector development [2][3] Group 2: Product Development and Market Position - The company has developed a portable multi-modal medical imaging system for emergency rescue applications, integrating portable DR and ultrasound devices [3][4] - The company’s industrial ultrasonic testing equipment is widely used in aerospace, petrochemicals, energy, and transportation sectors [4][5] - Key products include multi-modal medical imaging systems, specialized ultrasound diagnostic equipment, and automated non-destructive testing devices, which are expected to drive future revenue growth [5][6] Group 3: Research and Development - The company has participated in multiple national and provincial major research projects, with details disclosed in its prospectus and periodic reports [4][5] - The company has made advancements in AI-based breast cancer screening technology, enhancing the accuracy and efficiency of early detection [5][6] Group 4: Marketing and Sales Strategy - In 2025, the company will adjust its marketing strategy, focusing on major cities like Guangzhou, Shenzhen, Shanghai, and Beijing to strengthen its domestic and overseas marketing efforts [7][8] - The company aims to enhance its marketing network by attracting high-quality domestic and international distributors and improving local customer service capabilities [7][8] Group 5: Revenue Contribution - The sales revenue from surgical robots and automated non-destructive testing equipment constitutes a significant portion of the company's overall revenue [8]

证券代码：301602 证券简称：超研股份 公告编号：2025-045 汕头市超声仪器研究所股份有限公司 关于参加广东辖区上市公司 2025 年投资者网上集体接待日 活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，汕头市超声仪器研究所股份有限公司 （以下简称"公司"）将参加由广东证监局、广东上市公司协会联合举办的"2025 年广东辖区投资者集体接待日暨辖区上市公司中报业绩说明会活动"，现将相关 事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）参与本次互动交流，活动时间为 2025 年 9 月 19 日（周 五）15:30-17:00。届时公司高级管理人员、独立董事将在线就公司 2025 年半年 度业绩、公司治理、发展战略、经营状况等投资者关心的问题，与投资者进行沟 通与交流，欢迎广大投资者踊跃参与！ 特此公告。 汕头市超声仪器研究所股份有限公司 董事会 2025 年 9 月 16 日 ...